316 related articles for article (PubMed ID: 30009962)
1. Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers.
Dumestre-Pérard C; Clavarino G; Colliard S; Cesbron JY; Thielens NM
Autoimmun Rev; 2018 Sep; 17(9):890-899. PubMed ID: 30009962
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis.
Qi S; Chen Q; Xu D; Xie N; Dai Y
Lupus; 2018 Sep; 27(10):1582-1590. PubMed ID: 29720035
[TBL] [Abstract][Full Text] [Related]
3. [The roles of complement 1q and anti-C1q autoantibodies in pathogenesis of lupus nephritis].
Zhang FC; Zhou B; Dong Y
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):955-9. PubMed ID: 16061001
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis.
Caster DJ; Korte EA; Merchant ML; Klein JB; Wilkey DW; Rovin BH; Birmingham DJ; Harley JB; Cobb BL; Namjou B; McLeish KR; Powell DW
Proteomics Clin Appl; 2015 Dec; 9(11-12):1012-20. PubMed ID: 25824007
[TBL] [Abstract][Full Text] [Related]
5. Effect of Autoantibodies to Erythropoietin Receptor in Systemic Lupus Erythematosus with Biopsy-proven Lupus Nephritis.
Hara A; Furuichi K; Yamahana J; Yasuda H; Iwata Y; Sakai N; Shimizu M; Kaneko S; Wada T
J Rheumatol; 2016 Jul; 43(7):1328-34. PubMed ID: 27134248
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis.
Sjöwall C; Olin AI; Skogh T; Wetterö J; Mörgelin M; Nived O; Sturfelt G; Bengtsson AA
Autoimmunity; 2013 May; 46(3):205-14. PubMed ID: 23331132
[TBL] [Abstract][Full Text] [Related]
7. Novel Autoantigens Associated with Lupus Nephritis.
Onishi S; Adnan E; Ishizaki J; Miyazaki T; Tanaka Y; Matsumoto T; Suemori K; Shudou M; Okura T; Takeda H; Sawasaki T; Yasukawa M; Hasegawa H
PLoS One; 2015; 10(6):e0126564. PubMed ID: 26098692
[TBL] [Abstract][Full Text] [Related]
8. Association between the presence of anti-C1q antibodies and active nephritis in patients with systemic lupus erythematosus.
Gargiulo Mde L; Gómez G; Khoury M; Collado MV; Suárez L; Álvarez C; Sarano J
Medicina (B Aires); 2015; 75(1):23-8. PubMed ID: 25637896
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review.
Gatto M; Iaccarino L; Ghirardello A; Punzi L; Doria A
J Autoimmun; 2016 May; 69():1-11. PubMed ID: 26879422
[TBL] [Abstract][Full Text] [Related]
10. "Kill" the messenger: Targeting of cell-derived microparticles in lupus nephritis.
Nielsen CT; Rasmussen NS; Heegaard NH; Jacobsen S
Autoimmun Rev; 2016 Jul; 15(7):719-25. PubMed ID: 26970484
[TBL] [Abstract][Full Text] [Related]
11. Comparison of circulating miR-148a and miR-126 with autoantibodies as biomarkers of lupus nephritis in patients with SLE.
Omidi F; Khoshmirsafa M; Kianmehr N; Faraji F; Delbandi A; Seif F; Shekarabi M
J Immunoassay Immunochem; 2022 Nov; 43(6):634-647. PubMed ID: 35938736
[TBL] [Abstract][Full Text] [Related]
12. Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis.
Tsai CY; Li KJ; Shen CY; Lu CH; Lee HT; Wu TH; Ng YY; Tsao YP; Hsieh SC; Yu CL
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373215
[TBL] [Abstract][Full Text] [Related]
13. Circulating miR-181a and miR-223 expression with the potential value of biomarkers for the diagnosis of systemic lupus erythematosus and predicting lupus nephritis.
Abdul-Maksoud RS; Rashad NM; Elsayed WSH; Ali MA; Kamal NM; Zidan HE
J Gene Med; 2021 May; 23(5):e3326. PubMed ID: 33617143
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis.
Morell M; Pérez-Cózar F; Marañón C
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281193
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis.
Halfon M; Tankeu AT; Ribi C
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892349
[TBL] [Abstract][Full Text] [Related]
16. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
[TBL] [Abstract][Full Text] [Related]
17. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.
Batal I; Liang K; Bastacky S; Kiss LP; McHale T; Wilson NL; Paul B; Lertratanakul A; Ahearn JM; Manzi SM; Kao AH
Lupus; 2012 Jan; 21(1):13-26. PubMed ID: 21959138
[TBL] [Abstract][Full Text] [Related]
18. [Serological and histological study of lupus nephritis with special reference to anti-SSA antibody].
Nakashima A
Nihon Jinzo Gakkai Shi; 1989 Jul; 31(7):743-55. PubMed ID: 2585828
[TBL] [Abstract][Full Text] [Related]
19. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies.
Pradhan VD; Badakere SS; Bichile LS; Almeida AF
J Assoc Physicians India; 2004 Jul; 52():533-7. PubMed ID: 15645975
[TBL] [Abstract][Full Text] [Related]
20. Do circulating antibodies against C1q reflect the activity of lupus nephritis?
Smykał-Jankowiak K; Niemir ZI; Polcyn-Adamczak M
Pol Arch Med Wewn; 2011 Sep; 121(9):287-95. PubMed ID: 21860370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
